VKTX logo

VKTX
Viking Therapeutics Inc

38,175
Mkt Cap
$3.59B
Volume
1.22M
52W High
$43.15
52W Low
$22.96
PE Ratio
-7.45
VKTX Fundamentals
Price
$30.89
Prev Close
$30.68
Open
$30.58
50D MA
$32.78
Beta
1.62
Avg. Volume
2.35M
EPS (Annual)
-$3.19
P/B
7.13
Rev/Employee
$0.00
$3,258.03
Loading...
Loading...
News
all
press releases
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.
News Placeholder
More News
News Placeholder
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.
News Placeholder
Could Viking Therapeutics Be the Next Eli Lilly?
Key PointsEli Lilly dominates the weight loss drug market and competes with fellow pharma giant Novo Nordisk...
News Placeholder
Viking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics to Participate at Upcoming Investor Conferences Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire SAN DIEGO, May 21, 2026 SAN DIEGO, May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical...
News Placeholder
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party
Key PointsThere is a need for more weight loss drug options, including oral pills...
News Placeholder
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.
News Placeholder
Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.
News Placeholder
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 Viking Therapeutics Presents Data from its 13-Week Phase 2...
News Placeholder
NVO Rallies 21% in a Month: How Should Investors Play the Stock?
Novo Nordisk stock jumps 21% in a month after a Q1 beat and stronger GLP-1 demand, but pricing pressure and Eli Lilly rivalry still cloud its 2026 outlook.
News Placeholder
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?
Lilly surges after a Q1 beat and higher guidance, as Mounjaro and Zepbound fueled 56% revenue growth.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available